Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glycaemia and Cardiac Function in Patients With COVID-19 (GLYCOVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04410718
Recruitment Status : Recruiting
First Posted : June 1, 2020
Last Update Posted : June 1, 2020
Sponsor:
Information provided by (Responsible Party):
Andreas Andersen, Steno Diabetes Center Copenhagen

Brief Summary:

The study design is observational, exploratory study consisting of two cohorts of COVID-19 patients admitted to the ICU and the medical ward, respectively. The primary outcome focusing on the effect of plasma glucose levels on cardiac function will be evaluated by repeated assessment of cardiac function by echocardiography and measurement of plasma glucose. Furthermore, blood coagulability will be evaluated to determine the importance of diabetes status and plasma glucose changes for whole blood coagulability at time of admission to the ICU and progression in coagulability abnormalities. In the medical ward cohort, two assessments will be performed separated by no more than 12 hours. In the ICU cohort, three assessments will be performed separated by no more than 6 hours. Ideally, 60 patients with COVID-19 will be included in the ICU cohort with a 1:1 distribution between patient with and without diabetes. Ideally, 40 patients with diabetes will be included in the cohort of patients admitted to medical ward (hospitalisation cohort).

The primary hypothesis is that levels of plasma glucose have clinically significant impact on left ventricular systolic function in patients with COVID-19 admitted to the ICU. The secondary hypothesis is that the impact of plasma glucose on left ventricular systolic function is associated with glycaemic control prior to admission as measured by HbA1c.


Condition or disease Intervention/treatment
Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 COVID Other: Glycaemic levels

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Glycaemia and Cardiac Function in Patients With COVID-19
Actual Study Start Date : April 20, 2020
Estimated Primary Completion Date : October 30, 2020
Estimated Study Completion Date : November 30, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
The intensive care unit cohort
Patients (with or without diabetes) with COVID-19 admitted to the intensive care unit
Other: Glycaemic levels
Glycaemic levels during admission for COVID-19

The hospitalisation cohort
Patients with diabetes and COVID-19 admitted to the medical ward
Other: Glycaemic levels
Glycaemic levels during admission for COVID-19




Primary Outcome Measures :
  1. Plasma glucose levels and left ventricular ejection fraction [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    The within-subject effect of plasma glucose levels on left ventricular systolic function as measured by left ventricular ejection fraction (a pooled analysis of the hospitalisation cohort and ICU cohort)


Secondary Outcome Measures :
  1. Key secondary outcome: HbA1c, plasma glucose levels and left ventricular systolic function [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    Difference in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by left ventricular ejection fraction between patients with chronic hyperglycaemia prior to admission (HbA1c >53 mmol/mol) and with normoglycaemia prior to admission (HbA1c ≤53 mmol/l) (ICU cohort only)

  2. Plasma glucose levels and strain analysis [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    The within-subject effect of plasma glucose levels on left ventricular systolic function as measured by strain analysis (a pooled analysis of the hospitalisation cohort and ICU cohort)

  3. Plasma glucose levels and mitral annular systolic velocity [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    The within-subject effect of plasma glucose levels on left ventricular systolic function as measured by mitral annular systolic velocity (a pooled analysis of the hospitalisation cohort and ICU cohort)

  4. Plasma glucose levels and left ventricular ejection fraction (sub-group analysis) [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    Differences in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by left ventricular ejection fraction between the hospitalisation cohort, the ICU cohort with diabetes and the ICU cohort without diabetes, respectively

  5. Plasma glucose levels and strain analysis (sub-group analysis) [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    Differences in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by strain analysis between the hospitalisation cohort, the ICU cohort with diabetes and the ICU cohort without diabetes, respectively

  6. Plasma glucose levels and mitral annular systolic velocity (sub-group analysis) [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    Differences in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by mitral annular systolic velocity between the hospitalisation cohort, the ICU cohort with diabetes and the ICU cohort without diabetes, respectively

  7. HbA1c, Plasma glucose levels and strain analysis [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    Difference in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by strain analysis between patients with chronic hyperglycaemia prior to admission (HbA1c >53 mmol/mol) and with normoglycaemia prior to admission (HbA1c ≤53 mmol/l) (ICU cohort only)

  8. HbA1c, Plasma glucose levels and mitral annular systolic velocity [ Time Frame: The study applies a mixed model for assessment of within-subject effects by repeated assessment in same individual. The time frame is from first assessment until last assessment (max. 24 hours). ]
    Difference in the within-subject effect of plasma glucose levels on left ventricular systolic function as measured by mitral annular systolic velocity between patients with chronic hyperglycaemia prior to admission (HbA1c >53 mmol/mol) and with normoglycaemia prior to admission (HbA1c ≤53 mmol/l) (ICU cohort only)

  9. Diabetes status and whole blood coagulability and fibrinolysis [ Time Frame: At time of admission to the ICU (max. 24 hours after admission to the ICU) ]
    Difference in whole blood coagulability and fibrinolysis as measured by TEG between patients with and without diabetes at time of admission to the ICU (ICU cohort only)

  10. Diabetes status and change in whole blood coagulability and fibrinolysis during ICU stay [ Time Frame: From first until last assessment during ICU stay (max. 24 hours). ]
    Difference in change in whole blood coagulability and fibrinolysis as measured by TEG between patients with and without diabetes treated at the ICU (ICU cohort only)

  11. Prognostic value of TEG analysis [ Time Frame: From time of admission and until four weeks after admission ]
    The prognostic value of cardiac function and TEG on the following patient outcomes 1) need for treatment in the ICU (hospitalisation cohort only) 2) need for respirator treatment (hospitalisation cohort only) 3) COVID-19 related death

  12. Prognostic value of cardiac function [ Time Frame: From time of admission and until four weeks after admission ]
    The prognostic value of cardiac function on the following patient outcomes 1) need for treatment in the ICU (hospitalisation cohort only) 2) need for respirator treatment (hospitalisation cohort only) 3) COVID-19 related death

  13. Diabetes status and high-sensitivity troponins [ Time Frame: At the time of admission to the ICU (max. 24 hours after admission to the ICU) ]
    Difference in cardiac damage as measured by high-sensitivity troponin (hs-troponin) between patients with and without diabetes admitted to the ICU (ICU cohort only)

  14. Diabetes status and change high-sensitivity troponins [ Time Frame: From first until last assessment during ICU stay (max. 24 hours) ]
    Difference in change in cardiac damage as measured by high-sensitivity troponin (hs-troponin) between patients with and without diabetes admitted to the ICU (ICU cohort only)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The present study aims to evaluate the effect of glycaemia on cardiac function in patients with COVID-19 by examining cardiac function by echocardiography in two patient groups: 1) hospitalised COVID-19 patients with diabetes admitted to the medical ward 2) COVID-19 patients with or without diabetes admitted to the ICU.
Criteria

The ICU cohort - Inclusion criteria

  • Informed and written consent
  • Age ≥18 years
  • Verified COVID-19
  • Admission to the ICU within the last 24 hours
  • Type 1 or type 2 diabetes prior to admission (the diabetes sub-group only)

The ICU cohort - Exclusion criteria

  • Cardiac arrhythmia at time of inclusion (previously diagnosed paroxysmal atrial fibrillation will be allowed)
  • Pacemaker rhythm
  • Severe valve disease

The hospitalisation cohort - inclusion criteria

  • Informed and written consent
  • Age ≥18 years
  • Verified COVID-19
  • Admission to medical ward within the last 24 hours
  • Type 1 or type 2 diabetes prior to admission

The hospitalisation cohort - Exclusion criteria

  • Cardiac arrhythmia at time of inclusion (previously diagnosed paroxysmal atrial fibrillation will be allowed)
  • Pacemaker rhythm
  • Severe valve disease

Withdrawal criteria

- The participants may withdraw at will at any time


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04410718


Contacts
Layout table for location contacts
Contact: Andreas Andersen, MD +45 31717755 andreas.andersen.04@regionh.dk

Locations
Layout table for location information
Denmark
Herlev and Gentofte Hospital Recruiting
Hellerup, Please Select, Denmark, 2900
Contact: Andreas Andersen    31717755    andreas.andersen.04@regionh.dk   
Hvidovre Hospital Recruiting
Hvidovre, Please Select, Denmark, 2650
Contact: Andreas Andersen, MD    +45 31717755    andreas.andersen.04@regionh.dk   
Sponsors and Collaborators
Steno Diabetes Center Copenhagen
Layout table for additonal information
Responsible Party: Andreas Andersen, Principal Investigator, Steno Diabetes Center Copenhagen
ClinicalTrials.gov Identifier: NCT04410718    
Other Study ID Numbers: H-20024279
First Posted: June 1, 2020    Key Record Dates
Last Update Posted: June 1, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases